M.D. Anderson Cancer Center

Compiled by PlainTrial, Clinical Trial Intelligence Editorial Process · July 11, 2026

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).

2,692 total trials 549 currently recruiting 1201 completed early-phase tilt top decile by trial count

M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.

M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.

Top-decile sponsor footprint

M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,692 total, page 35 of 54

M.D. Anderson Cancer Center

Top-decile sponsor footprint

Open and recent trials

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

Lifestyle Intervention for High Risk Cancer Survivors

New Magnetic Resonance Imaging and Spectroscopy Software in the Improvement of Image Quality

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Breakthrough Dyspnea Fentanyl Study in Cancer Patients

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

Temsirolimus in Combination With Metformin in Patients With Advanced Cancers

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass

Selective Image Guided Resection of Axillary Lymph Nodes

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients

Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Rocking Motion: Physiologic Effect on the Surgical Stress Response

Study of 18F-Fluoro-PEG6-IPQA

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Comparison of a Novel 22-gauge Core Biopsy Needle

TKI258 for Metastatic Inflammatory Breast Cancer Patients

Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas

Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy

Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

Reducing Cancer Disparities Among Latinos in Texas

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Respiratory Syncytial Virus - RSV Protocol

Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia

Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

SB1518 for Patients With Myelodysplastic Syndrome (MDS)

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

In Vivo Dosimetry During Prostate Cancer Radiotherapy

Preoperative Treatment With Cetuximab and/or IMC-A12

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Phase Distribution

Therapeutic Areas

What is open in the M.D. Anderson Cancer Center pipeline

Related